Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Design issues in clinical trials.

J E Overall1

  • 1Department of Psychiatry and Behavioral Sciences, University of Texas Medical School, Houston 77225.

Progress in Clinical and Biological Research
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CLUSTER ORIENTED FACTOR SOLUTIONS: OBLIQUE POWERED VECTOR FACTOR ANALYSIS.

Multivariate behavioral research·2016
Same author

Common Misconceptions Concerning The Analysis Of Covariance.

Multivariate behavioral research·2016
Same author

MARKER VARIABLE FACTOR ANALYSIS: A REGIONAL PRINCIPAL AXES SOLUTION.

Multivariate behavioral research·2016
Same author

FACTOR STRUCTURE O F THE MMPI IN A PSYCHIATRIC POPULATION.

Multivariate behavioral research·2016
Same author

An Investigation Of The Consistency Of Diagnostic Concepts Among Five Child And Adolescent Psychiatrists.

Multivariate behavioral research·2016
Same author

Lever-pressing behavior of albino rats during prolonged exposures to x-radiation.

Project report. USAF School of Aviation Medicine·2014
Same journal

DNA homology and chromosome stability: a sensitive yeast genetic system for identifying double-stranded DNA damage.

Progress in clinical and biological research·2018
Same journal

Endotoxin and sepsis: molecular mechanisms of pathogenesis, host resistance, and therapy. Proceedings of the 4th Conference of the International Endotoxin Society. Nagoya, Japan, October 23-27, 1996.

Progress in clinical and biological research·1998
Same journal

The pathogenic role of LBP in gram-negative sepsis and septic shock.

Progress in clinical and biological research·1998
Same journal

The role of interleukin 6 in endotoxin-induced inflammatory responses.

Progress in clinical and biological research·1998
Same journal

Role of nitric oxide and reactive oxygen species in endotoxin shock.

Progress in clinical and biological research·1998
Same journal

Interaction of lipopolysaccharide with a mammalian lyso-phosphatidate acyltransferase (LPAAT) transfected into E. coli, and effect of lisofylline on LPAAT transfected into mammalian cells.

Progress in clinical and biological research·1998
See all related articles

This study explores optimal clinical trial designs for Alzheimer's disease drug development. It recommends specific methodologies for early and late-stage trials, emphasizing data analysis and reporting for effective evaluation.

Area of Science:

  • Clinical Trials
  • Neuroscience
  • Drug Development

Background:

  • Alzheimer's disease research requires careful consideration of clinical trial design and data analysis.
  • Different phases of drug development necessitate distinct experimental approaches.

Purpose of the Study:

  • To outline appropriate experimental designs for various stages of Alzheimer's disease clinical drug development.
  • To discuss data analysis considerations, including survival analysis and interim analyses.
  • To address statistical reporting issues, such as the use of one-tail p-values.

Main Methods:

  • Within-subject designs for early-phase trials.
  • Parallel-groups designs for large-scale, short-term efficacy studies.
  • Survival analysis models for placebo-controlled trials.

Related Experiment Videos

  • Interim analysis protocols for large-scale trials.

    • Main Results:

    • Within-subject designs are effective for early clinical trials.
    • Parallel-groups designs provide short-term efficacy evidence but require long-term evaluation.
    • Survival analysis aids in managing placebo-assigned patients.
    • Interim analyses allow for early decisions in large trials.

    Conclusions:

    • Appropriate trial design and data analysis are crucial for Alzheimer's disease drug development.
    • Methodological choices impact the evaluation of treatment efficacy and practical value.
    • Statistical reporting conventions should align with the nature of treatment effects and regulatory requirements.